Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Extending its duration of action has become a key focus in drug development
Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs
F.HanesworthJ
Compared with all control groups (basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly) and placebo), our results showed that tirzepatide was not significantly associated with an increased risk of pancreatitis (RR 1.46, [95% CI] 0.59 to 3.61
Treatment patterns in the later period were similar to those observed in the earlier period, where 50.0% of patients were receiving treatment at 1 year and the largest proportional increase in no exposure states occurred between the 90- and 180-day timepoints [17]
